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Abstract 
Colistin resistance in Enterobacteriaceae especially Klebsiella pneumoniae and Escherichia coli is driving the evolution 
of pan drug resistant strains. Screening a library of 13 plant nutraceuticals led to the identification of acetyl shikonin 
and ursolic acid, which exhibited synergy with colistin against extremely drug resistant (XDR) clinical strains of E. coli 
(U3790) and K. pneumoniae (BC936). Ursolic acid caused a significant colistin MIC reversal of 16-fold in U3790 and 
4-fold in BC936 strains. Ursolic acid also potentiated the bactericidal effect of colistin against both U3790 and BC936 
by causing ~ 4 to 4.5 log fold decline in CFU of both clinical isolates in a time kill assay. At 2× minimum effective 
concentration, ursolic acid was non-toxic to zebrafish as evidenced by brain and liver enzyme profiles and by histopa-
thology studies. In combination with colistin, ursolic acid reduced bacterial bioburden of U3790/BC936 by 1–1.58 log 
fold from the infected muscle tissue of zebrafish. Mechanistic explorations via studies on real time efflux, membrane 
potential and intracellular accumulation of dansyl chloride tagged colistin revealed that colistin efflux is inhibited by 
ursolic acid. In addition, ursolic acid also enhanced outer membrane permeability which probably facilitates colistin’s 
attack on outer and inner membranes. Our study shows that ursolic acid synergizes with colistin by inhibiting colistin 
efflux in Enterobacteriaceae that helps to curtail colistin resistant Enterobacteriaceae.
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Introduction
Multi drug resistant Enterobacteriaceae especially Kleb-
siella pneumoniae and Escherichia coli, are the leading 
causes of mortality and morbidity in neonatal bacte-
rial sepsis caused by Gram negatives. Roughly 54% of K. 
pneumoniae and 38% of E. coli strains that caused neona-
tal sepsis were observed to be multi drug resistant (Inves-
tigators of the Delhi Neonatal Infection Study (DeNIS) 
collaboration 2016). Colistin is regarded as a drug of 
last resort in therapeutic management of Gram negative 
infections (Yau et al. 2009) and colistin resistance in car-
bapenem resistant Enterobacteriaceae implies that we are 
in fact dealing with pan drug resistant strains, with very 
limited/no therapeutic options. Colistin resistance was 
known to be chromosomally mediated (Yau et al. 2009). 
But of late, studies have shown that plasmid encoded 
mcr-1 gene harbored by E. coli SHP47 confers colistin 
resistance in farm animals in China (Liu et al. 2016), sub-
sequently other reports have also highlighted spread of 
plasmid mediated colistin resistance in Europe (Skov and 
Monnet 2016). Resistance to colistin is typically caused 
by modification of LPS with 4-amino 4-dexoy arabinose 
or with phosphoethanolamine both of which alters sur-
face charge, ultimately resulting in reduced binding of 
colistin to outer membrane of the bacteria (Olaitan et al. 
2014). Among Enterobacteriaceae, especially with Kleb-
siella pneumoniae clinical isolates, mutation/disruption 
of mgrB was reported as the most common reason for 
colistin resistance (Cannatelli et al. 2014).
Due to resistance to last resort drugs like colistin, infec-
tions by MDR Enterobacteriaceae are associated with 
treatment failure and high mortality. Hence, restoring 
colistin sensitivity is likely to improve therapeutic out-
comes significantly. Towards this end, we were interested 
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to explore ability of natural products to interact syner-
gistically with colistin and augment bactericidal effect of 
colistin in clinical isolates of Enterobacteriaceae (espe-
cially E. coli and Klebsiella  pneumoniae.) both in  vitro 
and in  vivo in a zebrafish infection model that we and 
others have developed (Christena et al. 2016; Cheepuru-
palli et al. 2017). In addition, we were also interested in 
exploring mechanism of action of plant metabolites that 
displays synergistic interaction with colistin.
Materials and methods
Strains and compounds
Klebsiella pneumoniae reference strain (MTCC 432: K. 
pneumoniae-1) was procured from Microbial Type Cul-
ture Collection (MTCC) Chandigarh, India and E. coli 
MG1655 was  a kind gift from Dr. Aswin Sai Narayan 
Seshasayee  NCBS, Bangalore. The clinical isolates of 
Klebsiella pneumoniae and Escherichia coli were obtained 
from Sundaram Medical Foundation (SMF), Chen-
nai, India. The K. pneumoniae isolates are designated as 
(BC936, E474, BC1415, U2016, BC1994, BC2412, U3866) 
and the E. coli isolates as (U3176 and U3790). All the 
antibiotics, media and chemicals employed in the study 
were purchased from Sigma Aldrich, USA, Alfa-Aesar, 
USA or HiMedia, India. The plant metabolites used 
as test compounds was from a natural product library 
which include caffeic acid, naringin, naringenin, arjunolic 
acid, ursolic acid, acetyl shikonin, β-methylacrylshikonin, 
chrysin, chrysophenol, ventilone, ventiloquinone, emo-
din and physcion. Stocks for the test compounds were 
freshly prepared in DMSO and stored at − 20 °C for fur-
ther use.
Antimicrobial studies
All the test compounds were screened for their minimum 
inhibitory concentration (MIC) by microbroth 2-fold-
dilution method to check for the antimicrobial efficacy 
against the E. coli and K. pneumoniae strains as reported 
earlier (Andrews and Andrews 2001). Similarly, the sus-
ceptibility pattern of other clinical isolates towards other 
antibiotics was also analyzed.
Synergy and modulation of antibiotic resistance
To understand the combinatorial activity, plant metabo-
lites and antibiotics were used in combination at different 
concentrations by checkerboard assay against reference 
and clinical isolates as reported earlier (Lowrence et  al. 
2016). The Fractional inhibitory concentration (FIC) index 
was calculated and if FIC values are < 0.5, the interaction 
is synergistic, 0.5–2.0, interaction is additive and > 2, the 
interaction is antagonistic (Odds 2003). The colistin poten-
tiating ability of ursolic acid against colistin resistant iso-
lates of E. coli and K. pneumoniae was evaluated. Ursolic 
acid at sub-MIC concentration was used along with vary-
ing concentrations of colistin and incubated for 18–24 h at 
37 °C. The fold reduction in MIC (MIC reversal) of colistin 
when combined with ursolic acid was determined as mod-
ulation factor as reported earlier (Lowrence et  al. 2016; 
Sundaramoorthy et al. 2018).
Real time efflux study
To analyze the efflux pump inhibitory activity of ursolic 
acid against Klebsiella pneumoniae and Escherichia coli, 
real time efflux studies were performed using ethidium 
bromide as a substrate. The cells were de-energized, EtBr 
was added and then glucose was added to re-energize the 
cells, which would activate efflux. Resulting fluorescent 
intensity was measured with Ex 360 nm and Em 590 nm 
as reported earlier (Sundaramoorthy et  al. 2018). The 
increase in fluorescent intensity of EtBr was taken as a 
measure of efflux inhibition activity.
Time kill assay
Bactericidal effect of ursolic acid in combination with 
colistin was evaluated against the XDR clinical isolates 
U3790 and BC936 by time kill assay (Belley et  al. 2008; 
Grillon et al. 2016). Early log phase cells were subjected 
to following treatments, viz., colistin (4 μg/ml) and colis-
tin (4  μg/ml) + ursolic acid (40  µM). Untreated culture 
was maintained as a growth control. The samples were 
withdrawn at different time intervals (0, 1, 2, 3, 4, 5 and 
24 h), serially diluted and plated on agar plates. The plates 
were incubated at 37 °C for 24 h and from plate counts, 
Colony forming units (CFU)/ml was calculated and bac-
tericidal effect of combination was discerned.
Membrane permeability and integrity assay
NPN‑assay
The ability of ursolic acid to permeabilize outer membrane 
of Enterobacteriaceae was assessed by 1-N-phenylethyl-
amine (NPN) uptake assay as reported earlier (Helander 
and Mattila-Sandholm 2000). NPN exhibits enhanced 
fluorescence in phospholipid environment. Since the outer 
membrane (OM) of Gram negative bacteria affords steric 
hindrance to hydrophobic molecules and prevents NPN 
entry due to LPS, increased NPN fluorescence due to treat-
ment, indicates enhanced OM permeability. Briefly, cells 
were grown to mid-log phase collected and washed with 
5 mM HEPES buffer containing 0.2% glucose at pH 7.5 and 
resuspended in an equal volume of the same buffer. NPN 
was added at a concentration of 0.5 mM, this was immedi-
ately followed by addition of ursolic acid. Fluorescence due 
to NPN was measured (Ex 350 and Em 420 nm) using spec-
trofluorimeter (JASCO FP-8500, Jasco, Tokyo, Japan). NPN 
in buffer and NPN in buffer along with cells were main-
tained as controls.
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Membrane integrity assay
Compromise in cell membrane integrity due to treat-
ment with ursolic acid was assessed as reported previ-
ously (Marks et  al. 2013). Briefly, cells after treatment 
were collected at different time points (0, 1, 2, 3 and 
4  h), pelleted at 13,250 rcf for 5  min. The release of 
DNA and proteins, due to loss of inner membrane 
integrity, was quantified by measuring absorbance at 
260  nm and 280  nm respectively using UV–Vis Spec-
trophotometer (Evolution 201, Thermoscientific, USA). 
Treatment with 0.5% Triton X 100 was used as a posi-
tive control.
Membrane potential assay
The effect of ursolic acid alone/with colistin in perturb-
ing membrane potential was evaluated using DiSc3, a 
cationic membrane permeabilizing dye. Intact bacterial 
cells accumulate the dye in the lipid bilayer, resulting in 
quenching of fluorescence. When the membrane gets 
depolarized, dye gets released to the surrounding aque-
ous phase and fluorescence gets enhanced (Te Winkel 
et al. 2016). The fluorescent intensity (Ex 610 ± 5 nm and 
Em 660 ± 5 nm) of buffer with DiSc3 (1 μM) was meas-
ured initially. Mid log cells were added, which reduces 
the fluorescent intensity due to accumulation of dye in 
cells. Colistin, ursolic acid and colistin with ursolic acid 
treatments were given and the resulting variation in fluo-
rescence intensity due to various treatments was quanti-
fied using spectrofluorimeter (JASCO FP-8500, Jasco, 
Tokyo, Japan).
ROS assay
Release of reactive oxygen species (ROS) from XDR E. 
coli and K. pneumoniae clinical isolates, in the pres-
ence of colistin and ursolic alone and in combination 
was discerned using fluorophore Dichloro-dihydro-flu-
orescein diacetate (DCFH-DA) and fluorescence of ROS 
induced dichlorofluorescein (DCF) formation was quan-
tified using a fluorescence spectrophotometer (JASCO 
FP-8500, JASCO, Tokyo, Japan) (Ex 485  nm and Em 
538 nm).
Colistin accumulation studies
In order to visualize the intracellular accumulation of 
colistin within the cells, colistin was conjugated using 
the fluorophore dansyl chloride as reported earlier 
(Soon et  al. 2011). Intracellular accumulation of dan-
syl chloride conjugated colistin in response to different 
treatments viz., colistin-dansyl chloride, colistin-dansyl 
chloride + ursolic acid, colitin-dansyl chloride + CCCP 
was evaluated using fluorescent microscopic imaging 
(Nikon eclipse Ni-U, Nikon, Tokyo, Japan), to discern 
effect of various treatments on colistin accumulation.
Fish toxicity studies
All experiments were performed in compliance with 
applicable national and/or institutional guidelines for the 
care and use of animals (Animal Biosafety Level 2). Adult 
zebrafish (Danio rerio), either male/female, measuring 4 
to 5  cm in length, weighing approx. 300  mg, were pur-
chased from a local aquarium in Thanjavur, India. Ani-
mal acclimatization was performed as reported earlier 
(Westerfield 1995). To evaluate the effect of ursolic acid 
on brain and liver enzyme profiles of zebrafish, a total of 
10 fish were exposed to 32 mg/L of the respective com-
pounds for 48 h. At the end of exposure (48 h), fish were 
sacrificed (anesthetized by 150 mM MS-222 and eutha-
nized by decapitation), skin removed and the liver/brain 
from two fish from the same group were pooled and 
homogenized in ice-cold buffer (Tris–HCl, 0.1  M, pH 
7.4). The homogenate was centrifuged (10,000×g, 10 min, 
4 °C) and supernatant used for all analyses in duplicates. 
Protein was estimated by the method of Lowry et  al. 
(1951). Estimation of carboxyl esterase was essentially 
as described by Argentine and James (Argentine and 
James 1995) and acetylcholinesterase (AChE) activity was 
measured by Edmann’s degradation. Histopathology of 
ursolic acid injected fish was performed to analyze any 
histopathological alterations. The fish were sacrificed and 
fixed with 10% formalin. Thin sections were made after 
embedding process, stained with hematoxylin–eosin 
and viewed and imaged using a bright field microscope 
(Nikon Eclipse Ni-U, Japan).
Zebrafish infection
Intramuscular infection of zebrafish (n = 6) with colistin 
resistant Klebsiella pneumoniae BC936 and Escherichia 
coli U3790 strains corresponding to OD of 0.2 (~ 1 × 106 
CFU/ml) was performed as reported earlier (Neely et al. 
2002) with slight modifications. 2 h post infection, com-
pounds viz., ursolic acid/colistin alone and ursolic acid 
+colistin combination were administered via intramus-
cular injection as a single dose. 48 h post treatment, fish 
were euthanized, decapitated, muscle tissue was dis-
sected, minced, serial diluted and plated onto LB agar to 
discern colony counts after 24 h of incubation. Based on 
cell counts, graph was plotted and ability of ursolic acid 
alone and in combination with colistin to reduce bacte-
rial bioburden in infected muscle tissue was estimated.
Results
Antimicrobial profiling of isolates
The clinical isolates of Klebsiella pneumoniae and Escher-
ichia coli were obtained from blood of unrelated patients 
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diagnosed with bacterial sepsis from the same health 
care setting albeit at different time points. Antimicrobial 
profiling of clinical isolates showed that K. pneumoniae 
BC2412, U3866 and E. coli U3176 strains were relatively 
more sensitive to colistin whereas K. pneumoniae BC936 
and E. coli U3790 were the most colistin resistant strains, 
which also exhibits a very high MIC to most of the other 
antibiotics evaluated (Additional file 1: Table S1). Based 
on its resistance profile, both E. coli U3790 and K. pneu-
moniae BC936 strains were deemed as extremely drug 
resistant (XDR) strains as proposed by international 
expert committee for standard definitions on acquired 
resistance (Magiorakos et  al. 2012). We observed that 
U3790 and BC936 had a high colistin MIC (32  µg/ml), 
rest of the strains displayed an MIC (1–8 µg/ml) for colis-
tin. MIC of plant metabolites was determined against 
the XDR U3790 and BC936 strains wherein, most plant 
metabolites tested exhibited a higher MIC ranging from 
256 to 1028 µg/ml (Additional file 1: Table S2).
Synergy testing
Synergy between the plant metabolites and colistin was 
evaluated by checkerboard assay against U3790 and 
BC936. Among the metabolites evaluated, only acetyl shi-
konin and ursolic acid displayed synergy with U3790 and 
BC936 strains, the rest of the metabolites exhibited addi-
tive effect and emodin exhibited antagonistic effect. Both 
acetyl shikonin and ursolic acid were further evaluated for 
their ability to synergize with colistin against all strains 
employed in this study. Among the two metabolites cho-
sen, ursolic acid at 32 µg/ml displayed synergy with colis-
tin for most of the strains tested, other than one strain K. 
pneumoniae (BC1415) wherein FIC index values  were   
< 0.5. But acetyl shikonin displayed synergy only with four 
strains and for rest five strains, it exhibited an additive 
effect and hence it was not taken up further (Table 1).
Reversal of colistin MIC using ursolic acid
Ability of ursolic acid to reduce colistin MIC in all clini-
cal isolates was evaluated. Except for BC1415 strain of 
K. pneumoniae, with which ursolic acid did not display 
synergy and hence,  no decrease in colistin MIC was 
observed, for rest of the 8 strains (both E. coli and K. 
pneumoniae), ursolic acid caused 2–16-fold reduction in 
colistin MIC (Table 2). A 4-fold reduction in colistin MIC 
was seen for K. pneumoniae strains U3866, MTCC ref-
erence strains and BC936 strain whereas, 16-fold rever-
sal in colistin MIC was observed for the E. coli U3790 
strain. Thus by virtue of its synergistic interaction, ursolic 
acid was able to potentiate anti-bacterial effect of colis-
tin in various clinical isolates of Escherichia coli and K. 
pneumoniae. 
Time kill curve
In order to validate ability of ursolic acid to potentiate the 
bactericidal effect of colistin, a time kill assay was per-
formed. Overnight grown culture of U3790 and BC936 
were diluted to 0.1 OD and was subjected to following 
treatments: colistin alone, colistin and ursolic acid (16 µg/
ml)  and untreated sample was maintained as a growth 
control. In E. coli U3790 strain, 24 h plate counts revealed 
a 5–6 log increase in cell counts in the untreated control 
relative to starting population (Fig.  1a). Treatment with 
colistin caused an initial decline by 1  h, following which 
re-growth was observed, and by 24 h ~ 2 log CFU increase 
Table 1 Ursolic acid exhibits synergy with  colistin 
against most of the strains of Escherichia coli and Klebsiella 
pneumoniae 
Synergy implies FIC values < 0.5
Col + UR Col + AS
FIC index Effect FIC index Effect
E. coli
 U3790 0.19 Synergy 0.07 Synergy
 U3176 0.19 Synergy 0.37 Synergy
K. pneumoniae
 BC936 0.06 Synergy 0.06 Synergy
 U2016 0.50 Synergy 0.25 Synergy
 BC1415 1.06 Additive 1.03 Additive
 BC1994 0.38 Synergy 0.62 Additive
 MTCC K. pneu-
moniae
0.38 Synergy 1.25 Additive
 BC2412 0.38 Synergy 1.25 Additive
 U3866 0.25 Synergy 1 Additive
Table 2 Ursolic acid potentiates bacteriostatic 
effect of  colistin in  clinical isolates of  Escherichia coli 
and Klebsiella pneumoniae 
Strains MIC (μg/ml)
Col Col + UR Modulation 
factor
E. coli
 U3790 32 2 16
 U3176 1 0.5 2
K. pneumoniae
 BC936 32 8 4
 U2016 8 4 2
 BC1415 8 8 1
 BC1994 2 1 2
 MTCC K. pneumo-
niae
2 0.5 4
 BC2412 1 0.5 2
 U3866 1 0.125 4
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in cell count was observed relative to initial population. 
When ursolic acid was administered along with colistin, a 
steep decline in cell counts was noted by 1 h and by 24 h, 
a decline in cell count of ~ 4 log CFU relative to founder 
population was maintained (Fig. 1a). Similarly for K. pneu-
moniae BC936 strain, colistin treatment caused an initial 
decline at 3 h, but regrowth was observed by 24 h (Fig. 1b). 
Ursolic acid in combination with colistin caused a ~ 4.5-
fold reduction in bioburden, which was maintained until 
24 h, implying that ursolic acid effectively potentiated bac-
tericidal effect of colistin and restricted growth of both 
U3790 and BC936 strains for 24 h.
Zebrafish toxicity testing
Toxicity of ursolic acid was evaluated using by determin-
ing liver and brain enzyme profiles of zebrafish, because 
relative to in vitro cell culture based toxicity evaluation, 
whole organism based toxicity testing is likely to yield 
holistic insights (Astashkina et al. 2012). Liver and brain 
enzyme levels due to ursolic acid treatment were com-
parable as that of the untreated control implying that 
ursolic acid was non-toxic at the concentration tested 
(Fig.  2a, b). Whereas acetyl shikonin treatment resulted 
in enhanced acetylcholine esterase activity and alpha-
naphthol levels indicating toxicity. Histopathological 
analysis of liver and muscle from ursolic acid injected fish 
tissue sections revealed no signs of inflammation, neutro-
phil accumulation or tissue damage and tissue appeared 
similar to untreated control, showing non-toxic nature of 
ursolic acid at the tested concentration (Fig. 2c).
Zebrafish infection study
Zebrafish (n = 6 per group) was infected indepen-
dently  with ~ 1 × 106  CFU/ml (corresponding to an 
OD of 0.2) of   E. coli U3790 and K. pneumoniae BC936 
strains and 2  h post infection, fish were subjected to 
various treatments viz., colistin alone, ursolic acid alone 
and colistin and ursolic acid. Plate counts from infected 
muscle tissue of various groups showed that untreated 
control displayed a colony count of 5.2 log CFU. Colony 
counts in case of ursolic acid treatment group was com-
parable to untreated control at 5.7 log CFU. Colistin 
treatment resulted in a decline in plate count to 4.7 log 
CFU. When ursolic acid was administered in combina-
tion with colistin, a further reduction in plate count to 
3.62 log CFU was observed for U3790 strain. With BC936 
strain, treatment with colistin did not cause significant 
decline in cell counts relative to infected and untreated 
cells. The combination of ursolic acid and colistin caused 
1 log decline in plate counts. Most importantly treatment 
with combination caused statistically significant decline 
in cell counts for both E. coli U3790 (P = 0.003) and K. 
pneumoniae- BC936 (P = 0.0375), although the reduction 
in cell counts was more pronounced for U3790 strain. 
Thus relative to untreated control, ursolic acid-colistin 
combination caused 1.1 to 1.58 log CFU reduction in 
both U3790 and BC936 strains (Fig.  3). Reduction in 
Fig. 1 Time kill curve: UR potentiates the effect of colistin and causes growth reversal in resistant isolates of a E. coli U3790, b K. pneumoniae 
BC936. The culture was treated with colistin (Col—filled square) alone and colistin with ursolic acid (filled triangle). The samples were withdrawn at 
time intervals from 0, 1, 2, 3, 4 and 24 h and plated on to LB agar plates. The error bar represents the standard error of mean of three independent 
samples
(See figure on next page.)
Fig. 2 In vivo toxicity testing: Impact of ursolic acid on liver (a) and brain (b) enzyme activities. Liver α carboxyl esterase  and brain acetyl choline 
esterase activities were carried out using pooled liver/brain tissues from different fishes in the same group after 48 h of treatment. c Histopathology 
analysis: fish were injected with PBS and ursolic acid intramuscularly. After 48 h, the fish were sacrificed and preserved immediately in 10% formalin. 
They were embedded in paraffin blocks, sectioned, stained with Hematoxylin and eosin and imaged using bright field microscope. A–D represents 
histopathology of liver and muscle of untreated and ursolic acid (UR) treated respectively
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bioburden following combinatorial treatment highlights 
the ability of ursolic acid in potentiating bactericidal 
effect of colistin in vivo.
Membrane permeability
NPN was used as fluorophore to evaluate membrane 
permeability. In E. coli U3790, colistin treatment caused 
a slight increase in membrane permeability relative to 
untreated control and ursolic acid caused ~ 1.5-fold 
increase in membrane permeability. But when urso-
lic acid was mixed with colistin a significant 2.5-fold 
increase in membrane permeability was observed (Addi-
tional file 1: Fig S1). With K. pneumoniae BC936 strain, 
colistin treatment showed ~ 1-fold increase in mem-
brane permeability whereas ursolic acid caused ~ 0.8-fold 
increase in permeability. Combination of colistin with 
ursolic acid resulted in a 2.4-fold increase in membrane 
permeability. Thus ursolic acid synergistically enhanced 
membrane permeabilizing effect of colistin in both 
U3790 and BC936 strains. By enhancing membrane per-
meability ursolic acid would afford more access to colis-
tin and is likely to potentiate bactericidal effect of colistin.
Real time efflux studies (RTE)
To discern the ability of ursolic acid to inhibit efflux 
pumps, real time efflux assay was performed for U3790 
and BC936 strains. De-energized cells were incubated 
with ursolic acid for 1 h and then re-energized with glu-
cose and fluorescence of EtBr was measured over a time 
course of 20 min. PAßN and CCCP were maintained as 
positive controls. RTE results revealed that ursolic acid 
caused enhanced inhibition of EtBr efflux relative to 
positive controls PAßN and CCCP (Fig. 4). Thus ursolic 
acid apart from enhancing membrane permeability, also 
inhibits efflux pumps in Enterobacteriaceae.
Measurement of membrane potential
DiSc3 was used to determine the effect of ursolic acid 
with colistin on membrane potential. DiSc3 exhib-
its enhanced fluorescence in aqueous milieu and its 
fluorescence gets quenched when it partitions to lipid 
membranes of cells, compounds that alters membrane 
potential causes DiSc3 to partition back into aque-
ous environment resulting in enhanced fluorescence. 
In E. coli U3790 strain, addition of colistin and ursolic 
acid alone caused depolarization resulting in enhanced 
fluorescence. Combination of colistin with ursolic acid 
showed 2.5-fold enhanced depolarization effect relative 
to the individual components (Fig.  5). Even in K. pneu-
moniae BC936 strain, ursolic acid itself caused efficient 
depolarization, which was comparable to that of positive 
control CCCP. Colistin with ursolic acid showed ~ 2-fold 
increase in depolarization effect. This reveals that urso-
lic acid with colistin can disrupt membrane potential in 
both U3790 and in BC936 strains (Fig.  5). Membrane 
potential perturbation will abolish proton motive force, 
which energizes most of efflux transport proteins and 
hence by perturbing membrane potential ursolic acid 
inhibits efflux in Enterobacteriaceae.
Fig. 3 Ursolic acid synergistically potentiates bactericidal effect of colistin in infected zebrafish. E. coli U3790 and K. pneumoniae BC936 were 
intramuscularly injected in zebrafish and treated with either colistin (Col)/ursolic acid (UR) or colistin + ursolic acid in combination for 24 h. 
Following treatment, fish were euthanized and the muscle tissue was collected in PBS, homogenized, serially diluted and plated onto LB agar. The 
colony counts was scored after 24 h and represented as log CFU/ml. The error bar represents the standard error of mean of three independent 
samples
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Colistin accumulation studies
In order to confirm whether ursolic acid prevents colistin 
efflux, we qualitatively determined intracellular accumu-
lation of colistin by tagging colistin with dansyl chloride, 
which exhibits fluorescence and can be imaged using a 
fluorescent microscope. Incubation of colistin-dansyl 
chloride with bacterial cells in the presence and absence 
of ursolic acid for 3  h showed that there is enhanced 
uptake of colistin-dansyl chloride in the presence of urso-
lic acid (Fig. 6), which was comparable to accumulation 
of colistin-dansyl chloride seen in the presence of posi-
tive control (CCCP). This shows that colistin indeed gets 
accumulated within the cells in presence of ursolic acid, 
which could be attributed to efflux inhibitory potential 
of ursolic acid primarily mediated by its ability to disrupt 
proton motive force.
ROS generation
DCFH-DA was used as fluorophore to evaluate ROS 
production and in the presence of ROS, non-fluorescent 
DHFCA would be converted to strongly fluorescent DHF. 
Ursolic acid treatment caused only a minimum or neg-
ligible level of ROS production in bacterial cells relative 
to untreated cells. When treated with colistin, ~ 3–4-fold 
increases in ROS production was observed. Whereas 
when ursolic acid was combined with colistin there was 
reduction in ROS generation by ~ 1-fold in both U3790 
and BC936 strains (Additional file 1: Fig S2). Thus ursolic 
acid treatment quenches ROS production in Enterobacte-
riaceae. Overall ursolic acid enhances bactericidal effect 
of colistin by enhancing outer membrane permeability 
and by disrupting proton motive, which prevents colistin 
efflux and results in increased intracellular accumulation 
Fig. 4 Ursolic acid inhibits efflux pump in colistin resistant clinical isolates K. pneumoniae BC936 and E. coli U3790. The deenergized cells 
of K. pneumoniae BC936 and E. coli U3790 were treated with ursolic acid (UR) for 1 h. The cells were then reenergized with glucose and 
residual fluorescence of EtBr was measured for a time period of 0–20 min. Phenyl arginine beta naphthylamide (PABN) and Carbonyl cyanide 
m-chlorophenylhydrazine (CCCP) were maintained as positive controls (Filled diamonds—untreated cells; Empty circles—cells + EtBr; Empty 
triangles—PABN treated; Filled triangles—CCCP treated; Filled squares—ursolic acid treated). The experiment was performed in triplicates
Fig. 5 Ursolic acid with colistin causes effective membrane depolarization in E. coli U3790 and K. pneumoniae BC936. Mid log cells of U3790 and 
BC936 were treated with colistin (Col), ursolic acid (UR) and colistin + ursolic acid (Col + UR) in the presence of DiSc3. The fluorescent intensity was 
measured at Ex 605 nm and Em 665 nm
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of colistin, thereby leading to enhancement in bacteri-
cidal effect of colistin both in vitro and in vivo.
Discussion
The recent declaration of list of drug resistant priority 
pathogens by WHO urging R&D to develop new anti-
microbials, highlights the urgent need for addressing 
the issue of antimicrobial resistance. Incidentally as per 
World Health Organization (WHO) list, carbapenem 
resistant Enterobacteriaceae viz., Klebsiella pneumoniae 
and Escherichia coli belongs to the high priority cat-
egory, which requires urgent attention by researchers to 
develop new antimicrobial agents or resistance modula-
tory agents. Pentacyclic triterpenoids such as oleanolic 
acid and ursolic acid and their derivatives were discov-
ered earlier as potential alternatives to antibiotics against 
a broad spectrum of pathogens (Wolska et al. 2010; Wang 
et al. 2016). Ursolic acid was shown to display anti-Myco-
bacterium tuberculosis activity and immune-stimulatory 
activity by decreasing the microbial load in TB induced 
mice. Ursolic acid derivatives were also reported earlier 
to inhibit multidrug resistant E. coli when used in com-
bination with kanamycin (do Nascimento et  al. 2014) 
and were also shown to inhibit acrAB mediated efflux of 
nalidixic acid in E. coli. Ursolic and oleanic acids were 
earlier reported to synergize with beta lactam antibiot-
ics against gram positive pathogens S. aureus, S. epider-
midis and Listeria monocytogenes (Kurek et al. 2012). In 
a recent interesting study, ursolic and oleanic acids pre-
sent in dichloromethane extract of shea butter tree were 
shown to synergize with ampicillin and oxacillin against 
MRSA and cause reversion of MRSA phenotype which 
was attributed to delocalization of PBP2 from the septal 
division site leading to disturbance in peptidoglycan syn-
thesis, in addition the triterpenoids also caused indirect 
inhibition of β-lactamases and reversed β-lactam resist-
ance in MRSA (Catteau et  al. 2017). To the best of our 
knowledge, ursolic acid was not reported to interact syn-
ergistically with colistin in bacteria. We are reporting for 
the first time that ursolic acid can reverse colistin MIC in 
eight non replicate clinical isolates of Enterobacteriaceae 
viz., K. pneumoniae and E. coli.
Colistin is a drug of last resort in Enterobacteriaceae 
(Falagas et  al. 2005). In Gram negative bacteria, colistin 
is believed to cause outer membrane (OM) disruption 
by insertion of hydrophobic fatty acyl N terminal chain 
into outer membrane followed by entry into periplasm 
and thinning and lysis of inner membrane (Velkov et al. 
2010). Presently colistin resistant strains are managed by 
combinatorial therapy involving various antimicrobial 
agents whose therapeutic efficiency is not well estab-
lished (Cheng et al. 2018). A recent study has shown that 
use of outer membrane permeabilizing agents like anti 
protozoal drug pentamidine with Gram positive anti-
microbial agents can indeed be highly effective against 
colistin resistant Gram negative bacteria (Stokes et  al. 
2017). Follow up study by the same group has shown that 
colistin, by virtue of its membrane permeabilizing effect, 
in combination with clarithromycin is highly effective 
against mcr-1 harboring K. pneumoniae both in vitro and 
in vivo (MacNair et al. 2018). Colistin doripenem combi-
nation was found to be quite effective in curtailing both 
colistin resistant and colistin heteroresistant K. pneumo-
niae isolates (Deris et  al. 2012). In an effort to identify 
antibiotics that synergized with colistin against colistin 
resistant Enterobacteriaceae, among 20 different isolates 
Fig. 6 Colistin accumulation is enhanced in the presence of ursolic acid similar to CCCP. Mid log cells were incubated with colistin-dansyl chloride 
alone and along with ursolic acid (UR)/CCCP for 3 h and imaged using a fluorescent microscope. a Untreated, b colistin, c colistin + UR, d dansyl 
chloride, e colistin-dansyl chloride, f colistin-dansyl chloride + UR, g colistin-dansylchloride + CCCP
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tested, colistin in combination with linezolid, rifampin, 
azithromycin and fusidic acid exhibited synergistic activ-
ity against > 90% of the strains (Brennan-Krohn et  al. 
2018). Another recent study has shown that colistin sul-
phadiazine combination was synergistic and highly effec-
tive in curtailing 92.7% of 55 colistin resistant strains 
irrespective of mechanism of colistin resistance (Okdah 
et al. 2018).
In A. baumannii it was shown that colistins’ bacte-
ricidal effect was mediated by reactive oxygen species 
(ROS) especially •OH radical and the agents that impair 
production of ROS were shown to delay killing effect of 
colistin (Sampson et al. 2012). In the present study since 
ursolic acid quenched ROS and the amount of ROS gen-
erated by colistin was further reduced in the presence of 
ursolic acid (Additional file  1: Fig S2), enhancement of 
colistins’ bactericidal effect in the presence of ursolic acid 
(Fig. 1 and Table 2) cannot be attributed to ROS. In the 
absence of ROS, the synergistic effect of colistin –urso-
lic acid combination could be primarily attributed to 
inhibition of colistin efflux by ursolic acid which is sup-
ported by real time efflux data (Fig.  4) and by the abil-
ity of ursolic acid to disrupt membrane potential in both 
E. coli and K. pneumoniae (Fig. 5). By perturbing mem-
brane potential, which results in loss of proton motive 
force (PMF), efflux transport proteins that are powered 
by PMF are rendered non-functional. This is further sup-
ported by accumulation of dansyl tagged colistin within 
the cells (Fig. 6). In contrast, a previous study has shown 
that CCCP enhances bactericidal effect of colistin on A. 
baumannii cells but the authors contend that reduced 
metabolic activity due to CCCP, rather than efflux inhi-
bition, is responsible for increase in bactericidal effect 
of colistin (Park and Ko 2015). In the present study, we 
have shown that intracellular concentration of dansyl 
tagged colistin increases only in presence of CCCP and 
ursolic acid (Fig. 6), implying that colistin accumulates in 
presence of either ursolic acid/CCCP. It is implied that 
increased intracellular colistin accumulation accounts for 
enhanced bactericidal effect observed in combination. 
Another recent study has shown that CCCP is effective 
in potentiating bactericidal effect of only colistin but not 
tigecycline and meropenem against multi drug resistant 
Enterobacteriaceae (Osei Sekyere and Amoako 2017). 
Although an earlier study reported that ursolic acid syn-
ergized with nalidixic adid by inhibiting acrAB pump in 
E. coli using in silico studies, the authors have not used 
acrA/acrB knock out mutants to prove that ursolic acid 
specifically inhibits acrAB pump in E. coli (Dwivedi et al. 
2015). By virtue of its ability to disrupt proton motive 
force in both E. coli and K. pneumoniae as shown in the 
present study (Fig.  5), we can safely state that multiple 
efflux transporters that depend on PMF are inhibited 
concurrently, thereby preventing colistin efflux. Identify-
ing pump involved in colistin efflux requires gene knock 
out mutants of all pumps present in both E. coli and K. 
pneumoniae, which is quite labor intensive. Alternatively, 
gene expression studies by qPCR can identify pumps that 
are upregulated only in colistin resistant bacteria, this 
can be followed by creating gene knock outs of only those 
pumps that are overexpressed, such an approach can help 
to identify pump(s) responsible for colistin efflux, which 
can be pursued as a future study. Compounds that act as 
protonophores like CCCP are typically toxic to higher 
eukaryotes (Itami et al. 2015; Park et al. 2018). By virtue 
of being a nutraceutical and based on our observations 
on brain and liver enzyme profiles (Fig. 2a, b) and histo-
pathology studies (Fig. 2c), we can conclude that ursolic 
acid is non-toxic even at 2× concentration employed 
in present study, which gives credence for exploring 
it further as an adjuvant to colistin. A recent study has 
shown that curcumin can synergize with colistin and 
reduce persister formation in A. baumannii by increas-
ing ROS, enhancing membrane permeability and by 
inhibiting efflux, which ultimately eliminates persisters 
(Kaur et al. 2018). In the present study too, we observed 
that ursolic acid exhibited synergy with colistin against 
K. pneumoniae and E. coli clinical isolates and its mode 
of action involved enhancing the outer membrane per-
meability and perturbing membrane potential that ulti-
mately resulting in colistin accumulation, which enhances 
colistins’ attack on bacterial membranes. Although urso-
lic acid resembles curcumin in most of the other effects, 
by quenching ROS, it differs from curcumin and is prob-
ably slightly less effective. Hence future study would aim 
to make derivatives of ursolic acid that does not quench 
ROS, while retaining its ability to inhibit colistin efflux.
In conclusion from a library of 13 plant metabolites, we 
have screened and identified ursolic acid that interacts 
synergistically with colistin in clinical isolates of both K. 
pneumoniae and E. coli. By virtue of its synergistic inter-
action, ursolic acid caused colistin MIC reversal in both 
colistin resistant and colistin sensitive Enterobacteriaceae 
clinical isolates tested. Our observations revealed that 
ursolic acid was non-toxic and better potentiated bacte-
ricidal effect of colistin both in vitro, in a time kill assay 
and in vivo, in a zebrafish infection model against XDR 
strains U3790 and BC936 probably by enhancing access 
of colistin into the cells, which is achieved by perturbing 
outer membrane permeability and disrupting membrane 
potential that serves as a source of energy for multiple 
efflux pumps. Ability of ursolic acid to synergize with 
colistin highlights its therapeutic potential, which can be 
further enhanced by making derivatives that retain efflux 
inhibitory effect and gain ability of not quenching ROS. 
Ability of ursolic acid in potentiating bactericidal effect 
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of last resort drugs like colistin is interesting and war-
rants further studies with improved derivatives in higher 
animal models.
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